my ALT moved and I cannot work out whether dual agonist is why
Something I keep coming back to: my ALT moved and I cannot work out whether dual agonist is why. Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other. Nothing containing this compound is approved anywhere. Research-use-only…
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.
[deleted]
not approved anywhere, and the boards forget that constantly
read the histology endpoint definitions before quoting a response rate
That is an escalation schedule for an unapproved compound and this board does not host those.
glucagon agonism and energy expenditure is the mechanistic thread
Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.
Not convinced. Imaging-based fat fraction is not the same as a histological response and the paper is explicit about that.